Clinical Trials · NCT03056755
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 383
- Start date
- Aug 2017
- Locations
- 94 sites, 19 countries
- Primary endpoint
- Core Phase: Percentage of Participants Who Were Alive Without Disease Progression at 6 Months